Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 1301 - 1325 of 2538 in total

CEP-9722

CEP-9722 is under investigation in clinical trial NCT01345357 (Study of CEP-9722 in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors or Mantle Cell Lymphoma).
Investigational
Matched Iupac: … 14-methoxy-9-[(4-methylpiperazin-1-yl)methyl]-9,19-diazapentacyclo[10.7.0.0^{2,6}.0^{7,11}.0^{13,18}] …

ASN90

Investigational

SRP-9005

SRP-9005 is a rAAVrh74 vector containing a codon-optimized human SGCG transgene. Developed by the Kurt+Peter Foundation and Sarepta Therapeutics, it is being investigated for the treatment of Limb-girdle muscular dystrophy (LGMD) type 2C/R5.
Investigational

Rilotumumab

Rilotumumab has been investigated for the treatment of Cancer, Lung Cancer, Solid Tumors, Gastric Cancer, and Prostate Cancer, among others.
Investigational

NAP-226-90

Experimental

XL999

XL999 has the potential to provide benefit to patients with lung cancer and acute myelogenous leukemia. XL999 is a new chemical entity that inhibits a spectrum of receptor tyrosine kinases (RTKs) with growth promoting and angiogenic properties, including FGFR 1/3, PDGFRα/β, VEGFR2/KDR, KIT, and FLT3. XL999 also inhibits FLT4 and...
Investigational

PV903

PV903 is a self administered vaginally delivered recombinant protein for the treatment of recurrent miscarriage, resulting from an intolerant immune response to the developing foetus.
Investigational

TO-901317

TO-901317 is an LXRalpha and LXRbeta agonist.
Experimental

SKF-91488

Experimental

Technetium Tc-99m arcitumomab

Reduced Fab fragment of the murine IgG1 monoclonal antibody IMMU-4 (also called NP-4) with specificity for carcinoembryonic antigen (CEA) covalently labeled with Technitium 99. The molecule has a molecular weight of ~54,000 Daltons.
Experimental

NNC-55-0396 free base

NNC-55-0396 is a T-type Ca(2+) channel inhibitor.
Investigational

1-(9-ethyl-9H-carbazol-3-yl)-N-methylmethanamine

Experimental
Matched Name: … 1-(9-ethyl-9H-carbazol-3-yl)-N-methylmethanamine …
Matched Iupac: … [(9-ethyl-9H-carbazol-3-yl)methyl](methyl)amine …

Sugemalimab

Sugemalimab is a fully human, full-length IgG4 monoclonal anti-PD-L1 antibody discovered by CStone Pharmaceuticals and being investigated against relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma (R/R ENKTL) in adult patients and T-cell lymphoma.[L32868, L32873] It has been granted the Breakthrough Therapy Designation by the FDA to treat R/R ENKTL...
Investigational

Hydromethylthionine mesylate

Investigational

Xevinapant

Investigational

Yttrium Y-90 clivatuzumab tetraxetan

Yttrium Y-90 clivatuzumab tetraxetan is under investigation in clinical trial NCT00603863 (Safety and Efficacy Study of Different Doses of 90Y-hPAM4 Combined With Gemcitabine in Pancreatic Cancer).
Investigational

9-Butyl-8-(3-Methoxybenzyl)-9h-Purin-6-Amine

Experimental
Matched Name: … 9-Butyl-8-(3-Methoxybenzyl)-9h-Purin-6-Amine …
Matched Iupac: … 9-butyl-8-[(3-methoxyphenyl)methyl]-9H-purin-6-amine …

Fagrocorat

Experimental
Matched Iupac: … (4bS,7R,8aR)-4b-benzyl-7-hydroxy-N-(2-methylpyridin-3-yl)-7-(trifluoromethyl)-4b,5,6,7,8,8a,9,10-octahydrophenanthrene …

3-[2,6,8-Trioxo-9-[(2R,3R,4R)-2,3,4,5-tetrahydroxypentyl]-3H-purin-7-yl]propyl dihydrogen phosphate

Experimental
Matched Synonyms: … 5-Deoxy-5-{2,6,8-trioxo-7-[3-(phosphonooxy)propyl]-1,2,3,6,7,8-hexahydro-9H-purin-9-yl}-D-arabinitol …
Matched Name: … 3-[2,6,8-Trioxo-9-[(2R,3R,4R)-2,3,4,5-tetrahydroxypentyl]-3H-purin-7-yl]propyl dihydrogen phosphate …
Matched Iupac: … (3-{2,6,8-trioxo-9-[(2R,3R,4R)-2,3,4,5-tetrahydroxypentyl]-2,3,6,7,8,9-hexahydro-1H-purin-7-yl}propoxy …

Almonertinib

Almonertinib is a third-generation EGFR tyrosine kinase inhibitor targeting EGFR-sensitizing and T790M resistance mutations.[A231859, A231864, A231869] It is being investigated against advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC).
Investigational

N-(6,7,9,10,17,18,20,21-octahydrodibenzo[b,k][1,4,7,10,13,16]hexaoxacyclooctadecin-2-yl)acetamide

Experimental

Sri-9439

Experimental

CRA_9076

Experimental

CRA_9678

Experimental

DP-b99

DP-b99 is a newly developed lipophilic, cell permeable derivative of BAPTA (1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid), that is under development as a neuroprotectant for the potential treatment of stroke, head trauma and neurological damage associated with coronary artery bypass graft.
Investigational
Displaying drugs 1301 - 1325 of 2538 in total